InVitria optimizes hybridoma cell culture with Zap-Hybridoma

5 March 2010

InVitria’s launch of Zap-Hybridoma provides a powerful solution for hybridoma cell culture. Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product.

Zap-Hybridoma was developed by InVitria’s Cell Culture Development team as an answer to many of the challenges facing scientists working with hybridoma cell culture.

“Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum),” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development.

“We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer.”

“Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently,” said Scott Deeter, InVitria President and CEO. “We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance.”